Allergan's ALPHAGAN receives marketing approval for treatment of glaucoma.IRVINE, Calif.--(BUSINESS WIRE)--Sept. 9, 1996--Allergan Inc. (NYSE NYSE See: New York Stock Exchange :AGN AGN Again (Amateur Radio) AGN Active Galactic Nucleus AGN Acute Glomerulonephritis AGN Accountants Global Network AGN Air Gabon (ICAO code) ) on Monday announced that it has received clearance from the Food and Drug Administration to market ALPHAGAN(tm)(brimonidine) in the United States for the treatment of open-angle glaucoma o·pen-an·gle glaucoma n. Primary glaucoma in which the aqueous humor has free access to the trabecular reticulum. Also called simple glaucoma. and ocular hypertension. ALPHAGAN(tm) is a selective alpha-2 agonist Alpha-2 agonist (alpha-2 adrenergic receptor agonist) A class of drugs that bind to and stimulate alpha-2 adrenergic receptors, causing responses similar to those of adrenaline and noradrenaline. which significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. Its unique dual mechanism of action lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. "We are very pleased with this rapid approval," said Dr. Lester J. Kaplan, corporate vice president, science and technology. "This is the first alpha-2 agonist approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for the chronic treatment of open-angle glaucoma and ocular-hypertension, and will provide a new and important therapeutic option for management of these sight-threatening conditions." Glaucoma, an eye disease commonly characterized by excessive intraocular pressure, is a leading cause of blindness in the world. Allergan Inc., with headquarters in Irvine, is a technology-driven, global health care company, focused on specialty pharmaceutical products for specific disease areas that deliver value to customers, satisfy unmet medical needs and improve patients' lives. CONTACT: Allergan, Irvine Jeff D'Eliscu, 714/246-4636 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion